Clinical trials: Androgens
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
This randomized phase II trial studies if enzalutamide added to standard luteinizing hormone-releasing hormone (LHRH) analogue therapy will improve effects against prostate cancer compared to the standard therapy of LHRH analogue…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02058706
- Testing
- enzalutamide, bicalutamide, orchiectomy
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy
To determine the feasibility of using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen- deprivation therapy with external beam radiation therapy.
- Trial name
- NCT03535987
- Testing
- myocardial PET imaging
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer, Metastatic Prostate Cancer
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
This phase Ib single-center open-label de-escalation study uses a modified 3+3 design to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination of standard of care Sip-T and N-803 in patients…
- Trial name
- NCT07756593
- Testing
- Sipuleucel-T, N803
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor…
- Trial name
- NCT01889238
- Testing
- Enzalutamide
- Where
- 132 sites in United States, Belgium and 5 more
- Volunteers
- 118 people
- Sponsor
- Pfizer
Metastatic Castration-resistant Prostate Cancer
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).
- Trial name
- NCT06691984
- Testing
- Xaluritamig, Abiraterone, Enzalutamide
- Where
- 164 sites in United States, Australia and 20 more
- Volunteers
- 707 people
- Sponsor
- Amgen
Contraception, Hypogonadism
Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone
The purpose of this study is to test the how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future.
- Trial name
- NCT00161421
- Testing
- Oral Testosterone, Leuprolide (Lupron), Dutasteride
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Washington
Osteoporosis
Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )
Multi-center,double blind randomized phase III placebo controlled study in 250 men with histologically proven prostate cancer with out bone metastases who are beginning ADT therapy and who will receive concomitant treatment with…
- Trial name
- NCT00236002
- Testing
- Alendronate
- Volunteers
- 182 people
- Sponsor
- Canadian Urology Research Consortium
Prostate Cancer
Efavirenz in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate…
- Trial name
- FAVE (NCT00964002)
- Testing
- efavirenz
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Institut Bergonié
Metastatic Prostate Cancer, Recurrent Prostate Cancer
Impact of Atorvastatin on Prostate Cancer Progression During ADT
This randomized double-blind placebo-controlled trial tests whether intervention with atorvastatin delays development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for prostate cancer.
- Trial name
- ESTO2 (NCT04026230)
- Testing
- Atorvastatin 80mg
- Where
- 10 sites in Denmark, Estonia and 2 more
- Volunteers
- 400 people
- Sponsor
- Tampere University Hospital
Metastatic Castration-resistant Prostate Cancer
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with darolutamide in men with metastatic prostate cancer as first line hormonal…
- Trial name
- NCT07142551
- Testing
- Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Study of Oxaliplatin and Taxotere in Prostate Cancer
The primary objective for this study is to evaluate PSA response rates (response will be defined as a > 50% reduction in PSA levels) in men who have failed primary chemotherapy.
- Trial name
- NCT00260611
- Testing
- Oxaliplatin, Taxotere
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Pittsburgh
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who receive lorigerlimab in addition to…
- Conditions
- Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance
- Trial name
- NCT05848011
- Testing
- lorigerlimab, docetaxel, Prednisone
- Where
- 61 sites in United States, Australia and 8 more
- Volunteers
- 154 people
- Sponsor
- MacroGenics
Androgen Deprivation Therapy, Prostate Cancer
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer…
- Conditions
- Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic
- Trial name
- NCT05327465
- Testing
- Aerobic and resistance exercise, Usual Care
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
- Trial name
- ARANOTE (NCT04736199)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Androgen deprivation therapy (ADT)
- Where
- 131 sites in Australia, Brazil and 13 more
- Volunteers
- 669 people
- Sponsor
- Bayer
Hot Flashes
Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy
This study will look at the effects of a soy supplement called Revival on memory, quality of life, and hot flashes in men with prostate cancer who are being treated with testosterone suppression therapy.
- Trial name
- NCT00245518
- Testing
- Isoflavone
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Prostate Cancer
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical…
- Trial name
- NCT00658697
- Testing
- Docetaxel, Bevacizumab, ADT
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens.
- Trial name
- NCT00030654
- Testing
- bicalutamide, docetaxel, doxorubicin hydrochloride
- Where
- 78 sites in United States, Australia and 2 more
- Volunteers
- 21 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer Metastatic
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
Primary Objective: To compare the radiographic progression-free survival (rPFS) (using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for tumor lesions and Prostate Cancer Working Group 2 (PCWG2) criteria for bone scan…
- Trial name
- CARD (NCT02485691)
- Testing
- cabazitaxel XRP6258, enzalutamide, abiraterone acetate
- Where
- 65 sites in Austria, Belgium and 11 more
- Volunteers
- 255 people
- Sponsor
- Sanofi
Metastatic Cancer, Prostate Cancer
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone.
- Trial name
- NCT00634582
- Testing
- paricalcitol, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Androgenetic Alopecia
Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Previous studies of finasteride treatment in women with hair loss have failed to show positive results, yet, some women have responded anecdotally.
- Trial name
- NCT01052870
- Testing
- Finasteride
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- HairDx, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.